NICE guidance recommends individualised treatment approaches for type 2 diabetes and obesity management
health insurance system is a morass of complexity, administrative waste, and misaligned incentives that ultimately drives up costs and diminishes the patient experience
Semaglutide (Wegovy) received FDA approval specifically for chronic weight management in June 2021, legitimizing GLP-1 as a dedicated obesity treatment
The benefit of this product is that it is a powder so you can titrate the dosage for sensitive individuals
Older Adults Older individuals sometimes experience more fatigue on semaglutide because their metabolic flexibility (ability to adapt to different fuel sources) may be reduced compared to younger people
Lifestyle and dietary modifications are crucial for managing reflux alongside Wegovy: Eat smaller, more frequent meals rather than large portions, which can overwhelm your already-slowed digestive system Avoid lying down within 3 hours of eating to reduce reflux risk Identify and limit trigger foods such as caffeine, alcohol, chocolate, spicy foods, and high-fat meals Stay well-hydrated but avoid drinking large volumes with meals Elevate the head of your bed by 15-20cm if you experience night-time symptoms Maintain good posture during and after meals If reflux symptoms worsen or new symptoms develop whilst taking Wegovy, contact your GP
